FibroBiologics’ (FBLG) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research note released on Friday morning,Benzinga reports. D. Boral Capital currently has a $16.00 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of FibroBiologics in a research note on Wednesday, November 13th. Maxim Group assumed coverage on FibroBiologics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $12.00 target price on the stock. EF Hutton Acquisition Co. I raised FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, Rodman & Renshaw began coverage on FibroBiologics in a research report on Thursday, December 12th. They set a “buy” rating and a $12.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, FibroBiologics currently has a consensus rating of “Buy” and an average target price of $13.00.

FibroBiologics Price Performance

FibroBiologics stock opened at $2.36 on Friday. FibroBiologics has a 12-month low of $1.08 and a 12-month high of $55.00. The firm has a 50 day moving average of $2.66 and a 200 day moving average of $3.23.

Hedge Funds Weigh In On FibroBiologics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC raised its position in FibroBiologics by 363.2% during the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after acquiring an additional 31,331 shares in the last quarter. Geode Capital Management LLC boosted its position in FibroBiologics by 90.0% during the third quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after acquiring an additional 284,047 shares during the last quarter. Jane Street Group LLC purchased a new position in FibroBiologics during the third quarter worth approximately $37,000. State Street Corp grew its holdings in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock valued at $1,470,000 after purchasing an additional 99,789 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in FibroBiologics in the third quarter worth approximately $32,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.